EUROMACS, EACTS House, Windsor, UK.
Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany.
Eur J Cardiothorac Surg. 2022 Jun 15;62(1). doi: 10.1093/ejcts/ezac032.
In the third report of the European Registry for Patients with Mechanical Circulatory Support of the European Association for Cardio-Thoracic Surgery, outcomes of patients receiving mechanical circulatory support are reviewed in relation to implant era.
Procedures in adult patients (January 2011-June 2020) were included. Patients from centres with <60% follow-ups completed were excluded. Outcomes were stratified into 3 eras (2011-2013, 2014-2017 and 2018-2020). Adverse event rates (AERs) were calculated and stratified into early phase (<3 months) and late phase (>3 months). Risk factors for death were explored using univariable Cox regression with a stepwise time-varying hazard ratio (<3 vs >3 months).
In total, 4834 procedures in 4486 individual patients (72 hospitals) were included, with a median follow-up of 1.1 (interquartile range: 0.3-2.6) years. The annual number of implants (range: 346-600) did not significantly change (P = 0.41). Both Interagency Registry for Mechanically Assisted Circulatory Support class (classes 4-7: 23, 25 and 33%; P < 0.001) and in-hospital deaths (18.5, 17.2 and 11.2; P < 0.001) decreased significantly between eras. Overall, mortality, transplants and the probability of weaning were 55, 25 and 2% at 5 years after the implant, respectively. Major infections were mainly noted early after the implant occurred (AER<3 months: 1.44 vs AER>3 months: 0.45). Bilirubin and creatinine levels were significant risk factors in the early phase but not in the late phase after the implant.
In its 10 years of existence, EUROMACS has become a point of reference enabling benchmarking and outcome monitoring. Patient characteristics and outcomes changed between implant eras. In addition, both occurrence of outcomes and risk factor weights are time dependent.
在欧洲心胸外科协会机械循环支持患者注册处的第三份报告中,回顾了与植入时代相关的接受机械循环支持患者的结局。
纳入了成年患者(2011 年 1 月至 2020 年 6 月)的手术。来自随访完成率<60%的中心的患者被排除在外。结局分为 3 个时代(2011-2013 年、2014-2017 年和 2018-2020 年)。计算不良事件发生率(AER)并分为早期(<3 个月)和晚期(>3 个月)。使用单变量 Cox 回归分析探索死亡的风险因素,时间相关危险比(<3 个月与>3 个月)逐步变化。
共纳入 4834 例手术,涉及 4486 名患者(72 家医院),中位随访时间为 1.1 年(四分位间距:0.3-2.6)。植入物的年植入数量(范围:346-600)没有显著变化(P=0.41)。Interagency Registry for Mechanically Assisted Circulatory Support 分级(4-7 级:23%、25%和 33%;P<0.001)和住院死亡率(18.5%、17.2%和 11.2%;P<0.001)在各时代间均显著降低。总体而言,植入后 5 年的死亡率、移植和撤机率分别为 55%、25%和 2%。主要感染主要发生在植入后早期(AER<3 个月:1.44 vs AER>3 个月:0.45)。植入后早期胆红素和肌酐水平是显著的风险因素,但晚期不是。
EUROMACS 在其 10 年的存在期间,已成为基准比较和结果监测的参考点。患者特征和结局在植入时代之间发生了变化。此外,结局的发生和风险因素权重都是时间依赖性的。